BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shi X, Dou Y, Zhou K, Huo J, Yang T, Qin T, Liu W, Wang S, Yang D, Chang L, Wang C. Targeting the Bcl-2 family and P-glycoprotein reverses paclitaxel resistance in human esophageal carcinoma cell line. Biomedicine & Pharmacotherapy 2017;90:897-905. [DOI: 10.1016/j.biopha.2017.04.043] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Liu H, Ma D, Chen J, Ye L, Li Y, Xie Y, Zhao X, Zou H, Chen X, Pu J, Liu P. A targeted nanoplatform co-delivery of pooled siRNA and doxorubicin for reversing of multidrug resistance in breast cancer. Nano Res . [DOI: 10.1007/s12274-022-4254-1] [Reference Citation Analysis]
2 Dzobo K, Hassen N, Senthebane DA, Thomford NE, Rowe A, Shipanga H, Wonkam A, Parker MI, Mowla S, Dandara C. Chemoresistance to Cancer Treatment: Benzo-α-Pyrene as Friend or Foe? Molecules 2018;23:E930. [PMID: 29673198 DOI: 10.3390/molecules23040930] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
3 Jeddi F, Soozangar N, Sadeghi MR, Somi MH, Shirmohamadi M, Eftekhar-Sadat AT, Samadi N. Nrf2 overexpression is associated with P-glycoprotein upregulation in gastric cancer. Biomed Pharmacother 2018;97:286-92. [PMID: 29091877 DOI: 10.1016/j.biopha.2017.10.129] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 6.4] [Reference Citation Analysis]
4 Qin T, Liu W, Huo J, Li L, Zhang X, Shi X, Zhou J, Wang C. SIRT1 expression regulates the transformation of resistant esophageal cancer cells via the epithelial-mesenchymal transition. Biomed Pharmacother 2018;103:308-16. [PMID: 29656187 DOI: 10.1016/j.biopha.2018.04.032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
5 Kanno Y, Chen CY, Lee HL, Chiou JF, Chen YJ. Molecular Mechanisms of Chemotherapy Resistance in Head and Neck Cancers. Front Oncol 2021;11:640392. [PMID: 34026617 DOI: 10.3389/fonc.2021.640392] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Sundar R, Barr Kumarakulasinghe N, Huak Chan Y, Yoshida K, Yoshikawa T, Miyagi Y, Rino Y, Masuda M, Guan J, Sakamoto J, Tanaka S, Tan AL, Hoppe MM, Jeyasekharan AD, Ng CCY, De Simone M, Grabsch HI, Lee J, Oshima T, Tsuburaya A, Tan P. Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial. Gut 2021:gutjnl-2021-324060. [PMID: 33980610 DOI: 10.1136/gutjnl-2021-324060] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lowrence RC, Subramaniapillai SG, Ulaganathan V, Nagarajan S. Tackling drug resistance with efflux pump inhibitors: from bacteria to cancerous cells. Crit Rev Microbiol 2019;45:334-53. [PMID: 31248314 DOI: 10.1080/1040841X.2019.1607248] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
8 Bai Z, Gao M, Xu X, Zhang H, Xu J, Guan Q, Wang Q, Du J, Li Z, Zuo D, Zhang W, Wu Y. Overcoming resistance to mitochondrial apoptosis by BZML-induced mitotic catastrophe is enhanced by inhibition of autophagy in A549/Taxol cells. Cell Prolif 2018;51:e12450. [PMID: 29493085 DOI: 10.1111/cpr.12450] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
9 Das T, Anand U, Pandey SK, Ashby CR Jr, Assaraf YG, Chen ZS, Dey A. Therapeutic strategies to overcome taxane resistance in cancer. Drug Resist Updat 2021;55:100754. [PMID: 33691261 DOI: 10.1016/j.drup.2021.100754] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
10 Zhao J, Li L, Wang Z, Li L, He M, Han S, Dong Y, Liu X, Zhao W, Ke Y, Wang C. Luteolin attenuates cancer cell stemness in PTX-resistant oesophageal cancer cells through mediating SOX2 protein stability. Pharmacol Res 2021;174:105939. [PMID: 34655772 DOI: 10.1016/j.phrs.2021.105939] [Reference Citation Analysis]
11 Shi X, Qin T, Liu W, Zhang X, Li L, Huo J, Zhou K, Yang D, Zhang Y, Wang C. Selective anticancer activity of the novel steroidal dihydropyridine spirooxindoles against human esophageal EC109 cells. Biomed Pharmacother 2017;96:1186-92. [PMID: 29196102 DOI: 10.1016/j.biopha.2017.11.100] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
12 Wattanathamsan O, Thararattanobon R, Rodsiri R, Chanvorachote P, Vinayanuwattikun C, Pongrakhananon V. Tubulin acetylation enhances lung cancer resistance to paclitaxel-induced cell death through Mcl-1 stabilization. Cell Death Discov 2021;7:67. [PMID: 33824297 DOI: 10.1038/s41420-021-00453-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Li P, Zhong D, Gong PY. Synergistic effect of paclitaxel and verapamil to overcome multi-drug resistance in breast cancer cells. Biochem Biophys Res Commun 2019;516:183-8. [PMID: 31204050 DOI: 10.1016/j.bbrc.2019.05.189] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]